Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

Valerio Therapeutics Société anonyme

Valerio Therapeutics is a clinical-stage biotechnology company that develops innovative DNA decoy therapeutics for oncology and inflammatory diseases. Self-described as leading in the development of first-in-class treatments.

COM:VALERIOTX

Valerio Therapeutics

Last Close

0.08

25/11 08:24

Market Cap

15.49M

Beta: -

Volume Today

7.30K

Avg: -